Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Postel-Vinay

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Molecular Oncology|April 23, 2025
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Noé Herbel, Sophie Postel-Vinay
Biomedicines|March 25, 2022
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future DevelopmentsCarine Ngo, Sophie Postel-Vinay
Cancer Research|March 15, 2022
A Novel Synthetic Lethal Approach to Target MYC-Driven CancersRoman M Chabanon, Sophie Postel-Vinay
Bulletin Du Cancer|December 5, 2009
[Cancer and spirituality: the young oncologists' point of view]Sophie Postel-Vinay, Sarah Dumont, Hélène Marijon
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria
Seminars in Cancer Biology|October 1, 2019
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancersRoman M Chabanon, Daphné Morel, Sophie Postel-Vinay
Cancer Discovery|February 8, 2017
JAK Mutations as Escape Mechanisms to Anti-PD-1 TherapyAurelien Marabelle, Sandrine Aspeslagh, Sophie Postel-Vinay, et al.
Current Opinion in Molecular Therapeutics|October 7, 2009
Reovirus: Rationale and clinical trial updateRohit Lal, Dean Harris, Sophie Postel-Vinay, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
Novel Synthetic Lethal Therapeutic Strategies in Precision OncologyTimothy A Yap, Fiona Simpkins, Marie Porte, et al.
Seminars in Cancer Biology|December 28, 2019
Understanding genetic determinants of resistance to immune checkpoint blockersSandrine Aspeslagh, Roman M Chabanon, Stéphane Champiat, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Molecular Oncology|April 23, 2025
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Noé Herbel, Sophie Postel-Vinay
Biomedicines|March 25, 2022
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future DevelopmentsCarine Ngo, Sophie Postel-Vinay
Cancer Research|March 15, 2022
A Novel Synthetic Lethal Approach to Target MYC-Driven CancersRoman M Chabanon, Sophie Postel-Vinay
Bulletin Du Cancer|December 5, 2009
[Cancer and spirituality: the young oncologists' point of view]Sophie Postel-Vinay, Sarah Dumont, Hélène Marijon
European Journal of Cancer (Oxford, England : 1990)|August 18, 2020
Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria
Seminars in Cancer Biology|October 1, 2019
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancersRoman M Chabanon, Daphné Morel, Sophie Postel-Vinay
Cancer Discovery|February 8, 2017
JAK Mutations as Escape Mechanisms to Anti-PD-1 TherapyAurelien Marabelle, Sandrine Aspeslagh, Sophie Postel-Vinay, et al.
Current Opinion in Molecular Therapeutics|October 7, 2009
Reovirus: Rationale and clinical trial updateRohit Lal, Dean Harris, Sophie Postel-Vinay, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
Novel Synthetic Lethal Therapeutic Strategies in Precision OncologyTimothy A Yap, Fiona Simpkins, Marie Porte, et al.
Seminars in Cancer Biology|December 28, 2019
Understanding genetic determinants of resistance to immune checkpoint blockersSandrine Aspeslagh, Roman M Chabanon, Stéphane Champiat, et al.
Pageof 11